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Abstract Aim-The purpose of the study was to assess whether there was an increased rate of congenital anomalies or significant developmental delay in infants of women with epilepsy who had been treated with carbamazepine during pregnancy. Methods-47 children were studied, aged 6 months-6 years, who were born to 37 epileptic mothers on carbamazepine monotherapy (group A). All children had a complete physical and neurodevelopmental assessment by a developmental paediatrician, and 41 a complete psychological evaluation. They were compared with 47 children of similar socioeconomic status (group B). Results-Six of the 47 children in group A had typical facial features of 'carbamazepine syndrome'. The average cognitive score of children in group A was significantly lower than in group B. This was mainly because all six children with carbamazepine syndrome had a development quotient or intelligence quotient below 90. There were no differences between the two groups in physical growth or in the rate of major anomalies. Two children in group A had cleft palate but in each case this was found in a parent as well. Conclusions-In utero exposure to carbamazepine may result in 'carbamazepine syndrome' characterised by facial dysmorphic features and mild mental retardation. Prevalence of carbamazepine syndrome does not seem to be related to the dose of carbamazepine or the presence of maternal convulsions. It may depend upon heredofamilial factors that have yet to be defined. One possible factor is decreased activity of the enzyme epoxide hydrolase with resulting increased concentrations of carbamazepine epoxide which may be teratogenic. Carbamazepine is used for various central nervous system disorders including trigeminal neuralgia and cyclic manic-depressive disorder (bipolar digorder) and commonly in women with epilepsy.' It is usually well tolerated and is therefore used in pregnancy. The question whether this drug may affect the developing embryo and fetus is therefore of primary importance. '-13 While several investigators found no increase in the rate of congenital anomalies among offspring of epileptic mothers treated with carbamazepine during pregnancy,247 others have described an increased rate of congenital anomalies, further increased when epileptic women were treated with a combination of carbamazepine and other drugs such as valproic acid and phenobarbitone.Y" Although most investigators were not able to delineate a specific 'carbamazepine syndrome' Jones et al found an increase in facial dysmorphic features, that is short nose, long philtrum, upslanting palpebral fissures, hypertelorism, epicanthal folds, and nail hypoplasia." 12 These authors also described developmental delay in 20% of children (5/25). 12 The purpose of our study was to assess the incidence of congenital anomalies and the developmental outcome of 47 Two of the 49 children were excluded from analysis because of prematurity (born before 32 weeks of gestation). We matched 47 control children (group B) to the remaining 47 children (group A). These control children were matched by birth weight, gestational age, and parental socioeconomic status.
Socioeconomic status was ascertained according to parental profession and education, with one average score given to each family on a scale of 1-5, 1 being the highest.'6 The developmental psychologist did not know to which group a child belonged but the developmental paediatricians were not blinded. The ethnic origin of the parents and grandparents of the research group children was assessed, as 'Oriental' or 'Ashkenazi' (Eastern European). Among the 37 mothers there were 12 Ashkenazi women who gave birth to 17 children, 19 women of Oriental origin who gave birth to 24 children, and six women of unknown ethnic origin.
Results
The average birth weight, parental socioeconomic status, gestational age, age at examination, and several physical parameters are given in table 1. As observed, there were no differences between the groups in parental socioeconomic status, gestational age, birth weight, and average age at examination. The average height and head circumference at examination (shown in centiles) was similar in both groups.
All the mothers used carbamazepine as their sole anticonvulsant. The mean (SD) daily dose was 658 (329) mg, with a range of 200-1800 mg/day. Three mothers also used benzodiazepines for 1-3 weeks and five occasionally used drugs that have little or no effect on the central nervous system (antibiotics (2) , analgesics (2), and glucocorticosteroids (1)).
Fourteen of the mothers (47 pregnancies) had convulsions during their pregnancy. Among the 47 children in group A there were five children with major anomalies: hydrocephalus (1), ventricular septal defect (1), dila- tation of the pelvis of the kidney (1), and cleft palate (2) . The two children with cleft palate belonged to two families: only one had other features of carbamazepine embryopathy; his father also had cleft palate. The other child also had visual impairment and nystagmus and resembled his mother who had similar clinical findings. Of 47 children in group B there were three with major anomalies (one each with: pulmonic stenosis, hypospadias, and a solitary cyst of the kidney). Two additional children (one from each group) had unilateral dislocation of the hip. The striking finding was that in group A six children (table 1) had typical facial dysmorphic features as described in carbamazepine syndrome: upslanting palpebral fissure (6), epicanthic folds (6), micrognathia (4), broad nasal bridge (4), high arched palate (2,) or cleft palate (1). Two of these children also had strabismus, and one child had hypoplasia of the toe nails. Two of the children were born to Ashkenazi mothers and four to Oriental mothers, with no significant difference in ethnic origin. None of these six children were siblings. None of the control children had dysmorphic features or significant neurological impairment.
The cognitive and motor scores of the children are described in table 2 We found no correlation between the daily dose of carbamazepine and outcome. Of the four women on higher doses (1800 mg/day in one case and 1200 mg/day in three other cases), one child (in a woman treated with 1200 mg/day) had carbamazepine syndrome and a mental score (MDI) of 78. No correlation was found with the incidence of maternal convulsions during pregnancy. Of the 14 pregnancies complicated by convulsions only one child had carbamazepine syndrome. The mean (SD) socioeconomic status of the parents of the six children with carbamazepine syndrome was 2.8 (0.4), not statistically different from that of the other parents in group A (2.31(0.8)) or group B (2.14(0.8), table 1).
Discussion
The children born to epileptic mothers who were on carbamazepine monotherapy had lower average cognitive scores than controls, with six of the 47 children also exhibiting typical facial features of carbamazepine syndrome. The group is too small to conclude that the four major anomalies observedhydrocephalus, cleft palate, ventricular septal defect, and hydronephrosis were related to carbamazepine, especially as three control children had congenital anomalies.
Waters et al found three times more abnormal outcomes among offspring of epileptic women treated with anticonvulsants, when compared with controls.17 These included neonatal death and congenital anomalies. The higher rate of poor outcome was found in pregnant mothers treated with phenobarbitone.
Scolnick et al studied the outcome of women on carbamazepine or phenytoin monotherapy, and compared the results to matched controls.'8 They found that the global IQ of the children born to mothers on phenytoin monotherapy was 10 points lower than that of matched controls. However, the children born to carbamazepine exposed mothers did not differ from controls on various neurodevelopmental tests. 8 The average daily dose of carbamazepine used by the pregnant mothers was lower than the recommended adult maintenance dose, which may explain the lack of effects of carbamazepine in this study. 9 Women receiving phenytoin were on the conventionally recommended dose."
An obvious question when analysing our results is whether maternal epilepsy alone may be related to a reduction in a child's cognitive function. Holmes et al studied the mental development of 57 children born to epileptic women who had not received any medication during pregnancy.20 They found that the cognitive scores of these children, as measured by the Wechsler intelligence test, were similar to that of a group of matched control children.
Therefore, we suggest that the lower cognitive scores observed in our study were attributable to carbamazepine rather than to maternal disease. Moreover, low scores were mainly observed in the children that also had the typical facial dysmorphic features of carbamazepine syndrome.
Although one third of the women had seizures during their pregnancies, there was no association between the lower cognitive scores of the children or the appearance of clinical features of carbamazepine syndrome and the incidence of maternal seizures. Nor was there any association with the daily dose of carbamazepine. Scolnick et al'8 and Waters et all7 also found no correlation between the occurrence of seizures during pregnancy and outcome.
In our study, the six children with car- carbamazepine epoxide is toxic.' '3 Carbamazepine epoxide is actually found in the plasma of treated patients. It was found to be neither cytotoxic nor mutagenic, and the lethal dose is the same as that of carbamazepine.' 13 However, it is unproved whether carbamazepine epoxide is devoid of teratogenic effects. It is plausible that this or other enzymatic pathways may play a major part in carbamazepine induced embryopathy. Moreover, a low activity of epoxide hydrolase was found by Raymond et al in the amniocytes and placentas of two children with what appears to be carbamazepine induced congenital anomalies.24 It is therefore possible that there are genetic differences in the prevalence of people with low activity of epoxide hydrolase (or other enzymes) between populations, which may explain the different rates of carbamazepine induced congenital anomalies.
We found no difference in the ethnic origin of the children with and without carbamazepine syndrome in our study. Dr B Beuhler of the University of Nebraska Medical Center, Omaha, Nebraska has analysed for us 13 samples of amniocytes from epileptic women treated with phenytoin. In three cases enzyme activity was below 35%. The test was performed to evaluate the risk of the fetuses exposed in utero to phenytoin to develop phenytoin embryopathy. This is a rela-tively high rate and if low activity of epoxide hydrolase is related to carbamazepine embryopathy, it may explain the relatively high rate of carbamazepine syndrome in our study. We would therefore also expect to have a high prevalence of phenytoin embryopathy in our country, and these studies are now beginning to assess this.
